Corrigendum to “Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients” [Int. J. Cardiol. 124 (2008)166–171](Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients (2008)124(2)(166–171), (S0167527307003518), (10.1016/j.ijcard.2006.12.034));Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients

International Journal of Cardiology

Volumn 124, Issue 2, 2008, Pages 166-171

  van der Hoeven, B L ^a   Pires, N M M ^a,b   Warda, H M ^a   Putter, H ^a   Quax, P H A ^b   Schalij, M J ^a   Jukema, J W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Dexamethasone; Diabetes mellitus; Restenosis

Indexed keywords

DEXAMETHASONE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; SMOKING; SURVIVAL;

EID: 38749134908     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2019.02.049     Document Type: Erratum

References (10)

1. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol (1998) 584-589
2. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract (2005) 3-21
3. Moreno P.R., and Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol (2004) 2293-2300
4. Kornowski R., Mintz G.S., Kent K.M., et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation (1997) 1366-1369
5. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1172-1179
6. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 2273-2278
7. Liu X., De S.I., and Desmet W. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther (2004) 653-660
8. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol (2002) 1935-1942
9. Hoffmann R., Radke P.W., Ortlepp J.R., et al. Intravascular ultrasonic comparative analysis of degree of intimal hyperplasia produced by four different stents in the coronary arteries. Am J Cardiol (2004) 1548-1550
10. Cutlip D.E., Chauhan M.S., Baim D.S., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 2082-2089